ASEP Medical
Asep Inc. is dedicated to advancing patient care by developing innovative diagnostic and therapeutic solutions to combat antibiotic-resistant infections and sepsis. The company consolidates three development-stage companies—Sepset Bioscience, ABT Innovations, and SafeCoat Medical—and aims to mitigate the global crisis of antibiotic failure through rapid diagnostics and effective treatments. With extensive intellectual property, a large addressable global market, and a team of experienced leaders, Asep Inc. strives to become a global leader in the diagnosis and treatment of antibiotic-resistant infections.
Industries
Nr. of Employees
small (1-50)
ASEP Medical
Victoria, British Columbia, Canada, North America
Products
Rapid gene-signature sepsis diagnostic assay
A blood-based diagnostic assay using gene-expression signatures and AI to provide rapid (~1 hour) risk assessment and stratification for sepsis and related severe infections.
Peptide-based antibiofilm therapeutic and device coatings
Patented cationic peptide therapeutics with broad-spectrum activity against biofilm-associated, antibiotic-resistant bacteria, and substrate-independent peptide coatings designed to reduce device-related infections and improve sterile surfaces.
SepsetER
A gene-based diagnostic assay that rapidly diagnoses sepsis and organ failure within approximately 1 hour using blood samples, significantly shortening the time to diagnosis and enabling earlier patient treatment.
Sepset ER
A novel rapid diagnostic assay for the early and rapid risk assessment of sepsis based on molecular signatures of the immune response, delivering results in approximately one hour.
Gene-signature-based test
A rapid diagnostic test providing reliable sepsis test results in about 1 hour based on gene signatures, offering higher sensitivity and specificity than SIRS or Sepsis 3 criteria.
Diagnostic Sepsis Assay
Novel assay providing earlier and faster risk assessment of sepsis to enable targeted treatment.
Rapid gene-signature sepsis diagnostic assay
A blood-based diagnostic assay using gene-expression signatures and AI to provide rapid (~1 hour) risk assessment and stratification for sepsis and related severe infections.
Peptide-based antibiofilm therapeutic and device coatings
Patented cationic peptide therapeutics with broad-spectrum activity against biofilm-associated, antibiotic-resistant bacteria, and substrate-independent peptide coatings designed to reduce device-related infections and improve sterile surfaces.
SepsetER
A gene-based diagnostic assay that rapidly diagnoses sepsis and organ failure within approximately 1 hour using blood samples, significantly shortening the time to diagnosis and enabling earlier patient treatment.
Sepset ER
A novel rapid diagnostic assay for the early and rapid risk assessment of sepsis based on molecular signatures of the immune response, delivering results in approximately one hour.
Gene-signature-based test
A rapid diagnostic test providing reliable sepsis test results in about 1 hour based on gene signatures, offering higher sensitivity and specificity than SIRS or Sepsis 3 criteria.
Diagnostic Sepsis Assay
Novel assay providing earlier and faster risk assessment of sepsis to enable targeted treatment.
Services
Structuring and executing licensing agreements and joint ventures to support regional regulatory approval and commercialization of diagnostic and therapeutic technologies.
Design, conduct and coordination of preclinical efficacy studies and clinical validation studies for diagnostics and therapeutics, including independent study collaborations.
Structuring and executing licensing agreements and joint ventures to support regional regulatory approval and commercialization of diagnostic and therapeutic technologies.
Design, conduct and coordination of preclinical efficacy studies and clinical validation studies for diagnostics and therapeutics, including independent study collaborations.
Expertise Areas
- Sepsis diagnostics and stratification
- Antibiofilm and peptide therapeutics
- Peptide-based medical device coatings
- Diagnostic AI and machine-learning models
Key Technologies
- Gene-expression profiling
- AI / machine learning for diagnostics
- Biomarker signature assays
- Peptide therapeutics